NRx Pharmaceuticals (NASDAQ:NRXP) Releases Earnings Results, Misses Expectations By $0.10 EPS

NRx Pharmaceuticals (NASDAQ:NRXPGet Free Report) issued its quarterly earnings results on Friday. The company reported ($0.30) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.10), Zacks reports.

NRx Pharmaceuticals Stock Up 13.5 %

Shares of NRXP traded up $0.28 during midday trading on Friday, reaching $2.35. 247,402 shares of the stock were exchanged, compared to its average volume of 448,145. The company has a market cap of $39.75 million, a price-to-earnings ratio of -1.10 and a beta of 1.22. NRx Pharmaceuticals has a 12-month low of $1.10 and a 12-month high of $6.01. The firm has a 50 day simple moving average of $3.03 and a 200-day simple moving average of $2.02.

Wall Street Analyst Weigh In

A number of brokerages have commented on NRXP. D. Boral Capital restated a “buy” rating and set a $31.00 price objective on shares of NRx Pharmaceuticals in a research report on Tuesday, January 28th. Ascendiant Capital Markets increased their price target on shares of NRx Pharmaceuticals from $44.00 to $45.00 and gave the stock a “buy” rating in a research report on Monday, December 2nd. Finally, HC Wainwright reiterated a “buy” rating and issued a $19.00 price objective on shares of NRx Pharmaceuticals in a research note on Friday.

Get Our Latest Stock Analysis on NRx Pharmaceuticals

Insider Activity at NRx Pharmaceuticals

In related news, Chairman Jonathan C. Javitt purchased 40,000 shares of NRx Pharmaceuticals stock in a transaction on Tuesday, December 17th. The stock was bought at an average price of $1.17 per share, with a total value of $46,800.00. Following the completion of the transaction, the chairman now directly owns 84,634 shares of the company’s stock, valued at approximately $99,021.78. This represents a 89.62 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 19.00% of the stock is currently owned by company insiders.

NRx Pharmaceuticals Company Profile

(Get Free Report)

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.

See Also

Earnings History for NRx Pharmaceuticals (NASDAQ:NRXP)

Receive News & Ratings for NRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.